首页> 外文期刊>Clinical and applied thrombosis/hemostasis >Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
【24h】

Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.

机译:冠状动脉旁路移植术后与阿托伐他汀联合使用时,氯吡格雷对血小板活性的抑制作用明显大于阿司匹林:一项前瞻性随机研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: We aimed to compare the effects of 2 different antiplatelet agents on platelet activity in patients receiv- ing atorvastatin after coronary artery bypass grafting (CABG). METHODS: We prospectively randomized 50 patients undergoing CABG into 2 groups; group 1 started to receive atorvastatin (10 mg) plus clopidogrel (75 mg; C + A, n = 25) and group 2 atorvastatin (10 mg) and acetylsalicylic acid (ASA; 300 mg, ASA + A, n = 25) daily on postoperative day 1 and continued for 6 months after operation. Adenosine diphosphate (ADP)-induced platelet aggregation and the expressions of glycoprotein (Gp) IIb, GpIIIa, P-selectin, and fibrinogen (Fg) and low-density lipoprotein (LDL) binding to platelets were assessed preoperatively and at postoperative days 7, 90, and 180. RESULTS: The mean age of the patients was 59.6 +/- 7.6 years, and 82% of the patients were males. The combination of C + A markedly inhibited ADP-induced platelet aggregation compared with ASA + A at postoperative days 90 and 180 (52% +/- 6.0% vs 56% +/- 7.25% and 19.6% +/- 3.2% vs 37% +/- 4.1%, P = .039 and P = .0001, respectively). The therapy of C + A significantly suppressed the expressions of GpIIIa at postoperative days 7, 90, and 180 (P = .0001, P = .0001, and P = .0001, respectively) and P-selectin at postoperative days 90 and 180 (P = .035 and P = .002, respectively) when compared to ASA + A. The expression of GpIIb was also significantly depressed at postoperative day 180 in group 1 when compared to group 2 (P = .0001). Low-density lipoprotein binding was significantly increased at day 180 postoperatively in both the groups (basal: 42.9% +/- 5.6% vs 45.3% +/- 4.4% and day 180: 60.3% +/- 4.6% vs 61.8% +/- 5.7%, P = .0001). CONCLUSIONS: Our results demonstrate that the combination of C + A is more effective than that of ASA + A in inhibiting ADP-mediated platelet aggregation and expression of major platelet receptors after CABG.
机译:目的:我们旨在比较两种不同的抗血小板药物对接受冠状动脉搭桥术(CABG)后接受阿托伐他汀的患者的血小板活性的影响。方法:我们将50例行CABG的患者随机分为两组。第1组开始接受阿托伐他汀(10 mg)加氯吡格雷(75 mg; C + A,n = 25)和第2组阿托伐他汀(10 mg)和乙酰水杨酸(ASA; 300 mg,ASA + A,n = 25)在术后第1天,并在手术后持续6个月。术前和术后第7天评估了二磷酸腺苷(ADP)诱导的血小板凝集以及糖蛋白(Gp)IIb,GpIIIa,P-选择蛋白和纤维蛋白原(Fg)和低密度脂蛋白(LDL)与血小板结合的表达,结果:患者的平均年龄为59.6 +/- 7.6岁,其中82%为男性。在术后90天和180天,与ASA + A相比,C + A的组合显着抑制了ADP诱导的血小板凝集(52%+/- 6.0%vs 56%+/- 7.25%和19.6%+/- 3.2%vs 37 %+/- 4.1%,分别为P = .039和P = .0001)。 C + A疗法在术后第7、90和180天显着抑制了GpIIIa的表达(分别为P = .0001,P = .0001和P = .0001)和在术后90和180天的P-选择素的表达。与ASA + A相比(分别为P = .035和P = .002)。与第2组相比,第1组术后180天时GpIIb的表达也显着降低(P = .0001)。两组术后180天的低密度脂蛋白结合显着增加(基础:42.9%+/- 5.6%vs 45.3%+/- 4.4%和180天:60.3%+/- 4.6%vs 61.8%+ / -5.7%,P = .0001)。结论:我们的结果表明,C + A的组合比ASA + A的组合更能有效抑制CABG后ADP介导的血小板凝集和主要血小板受体的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号